Immunic Therapeutics
New York · Founded 2016
About Immunic Therapeutics
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR╬│t, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $994.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:IMUX
- Website: https://www.imux.com
- Phone: +4989208047700
Industries & Categories
Biotechnology, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immunic-therapeutics-156859 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.